|
市場調查報告書
癌症治療藥物的產品線資料庫
Oncology Pipeline Database
|
癌症治療藥物的產品線資料庫 是由出版商La Merie Publishing在2010年02月所出版的。
這份英文市場調查報告書價格從美金2509起跳。
本報告，針對癌症治療藥物的產品線動態進行調查分析，並將3,000件以上計畫的各種數據資料彙整成線上資料庫，以年度訂閱的方式，由下列摘要形式闡述。
刊載內容
- 計畫一覽表
- 藥品碼
- 標靶/作用機制
- 化合物分級
- 產品類型
- 企業
- 領域
- 治療領域
- 適應症
- R&D階段
- 產品類型
- 抗體
- 細胞
- DNA
- 醫療設備/生物材料
- 縮氨酸
- 蛋白質
- 放射性藥物
- RNA
- 小分子
- 疫苗
- 卷軸下移選單的預先定義標的
- ADC
- 極光激脢抗化劑
- Bcr-Abl・Src激脢抗化劑
- c-MET/HGF 抗化劑
- CD3抑制劑
- CD19抑制劑
- CD20抗體
- CD22抗體
- CD30抗體
- CD40/L
- CEA抗體
- CHK・KSP/Eg5抗化劑
- CXCR・CXCL致效劑 & 抑制劑
- 死亡受體TRAIL-R1/2
- EGF-R致效劑・抑制劑
- EpCAM抑制劑
- G-CSF・GM-CSF
- HDAC抗化劑
- Hsp90抗化劑
- HIF（Hypoxia-Inducible Factor）
- IGF-1R抑制劑
- 免疫細胞激素
- 免疫毒素
- 整合素抑制劑
- 干擾素
- JAK抗化劑
- MEK抗化劑
- 新型有絲分裂激脢抗化劑
- PARP抗化劑
- PDGF-R致效劑・抑制劑
- PI3K-AKT-mTOR抗化劑
- Plk-1抗化劑
- 蛋白酶體抗化劑
- Raf抗化劑
- Ras-Raf-MEK-ERK抗化劑
- SERM（選擇性雌激素接受體調理劑）
- TGF-R致效劑・抑制劑
- TPO（Thrombopoiesis刺激劑）
- TLR（Toll-Like Receptor）致效劑・抑制劑
- TRAIL-R1/R2 (死亡受體)
- VEGF・VEGF-R致效劑・抑制劑
Abstract
Product description
Subscription to La Merie's proprietary Oncology Pipeline Database provides
online access to more than 3,000 project entries in oncology. Each project is
specified for its Target or Mechanism of Action, Product Category and R&D
Phase. Use of the R&D database of cancer drugs is intuitive. Data sets of
interest can be printed and exported. Projects are being updated continuously.
The R&D history of each project with online references of information sources
can be viewed and printed. Sales figures of major products are provided. The
projects can be segmented into Territories, Product Categories and R&D Phases.
An advanced search function allows to combine search parameters. A scroll down
menu for predefined targets conveniently selects projects of interest. By
clicking on column heads of the project list, projects can be arranged in
ascending or descending alphabetical or numerical order, e.g. for phase,
product category or company name.
Sample screenshots illustrate the database.
Purchase of the subscription provides a 1-year online access to the data of
the Oncology Database. Credentials to access the database will be sent by
e-mail within 24 hours after purchase.
Benefits from the Oncology Pipeline Database:
- New database with no historical burden
- Intuitive use
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Product Categories:
- Antibodies
- Cells
- DNA
- Medical Devicer / Biomaterial
- Peptide
- Protein
- Radiopharmaceutical
- RNA
- Small Molecule
- Vaccine
Predefined Targets of the Scroll Down Menu:
- Antibody-Drug Conjugates (ADC)
- Aurora Kinase Inhibitors
- Bcr-Abl and Src Kinase Inhibitors
- c-MET/HGF Inhibitors
- CD3 Antagonists
- CD19 Antagonists
- CD20 Antibodies
- CD22 Antibodies
- CD30 Antibodies
- CD40/L
- CEA Antibodies
- CHK and KSP/Eg5 Inhibitors
- CXCR and CXCL Agonists & Antagonists
- Death Receptors TRAIL-R1/2
- EGF-R Agonists and Antagonists
- EpCAM Antagonists
- G-CSF and GM-CSF
- HDAC Inhibitors
- Heat shock protein 90 (Hsp90) Inhibitors
- Hypoxia-Inducible Factor (HIF)
- IGF-1R Antagonists
- Immunocytokines
- Immunotoxins
- Integrin Antagonists
- Interferon
- Janus Kinase (JAK) Inhibitors
- MEK Inhibitors
- Novel Mitotic Kinase Inhibitors
- PARP Inhibitors
- PDGF-R Agonists and Antagonists
- PI3K-AKT-mTOR Inhibitors
- Polo-like Kinase 1 (Plk-1) Inhibitors
- Proteasome Inhibitors
- Raf Inhibitors
- Ras-Raf-MEK-ERK Inhibitors
- Selective Estrogen Receptor Modulators (SERM)
- TGF-R Agonists and Antagonists
- Thrombopoiesis Stimulating Agents (TPO)
- Toll-Like Receptor (TLR) Agonists and Antagonists
- TRAIL-R1/R2 (Death Receptors)
- VEGF and VEGF-R Agonists and Antagonists
|
